Business Context and Reporting Period
ImmuCell Corporation (ICCC), a Delaware corporation headquartered in Portland, Maine, filed this Form 8-K on April 8, 2025. The report addresses preliminary, unaudited product sales for the quarter ended March 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that a press release containing these preliminary sales figures has been issued and is attached as Exhibit 99.1.
Material Changes
No material changes versus the prior comparable period are detailed within the body of this Form 8-K. The report references an external press release for the specific operational results.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk disclosures regarding the reported period. The document explicitly states that the information in the attached press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 8, 2025) for the actual preliminary sales figures.
- Verify the unaudited nature of the reported sales data.
- Confirm the trading symbol (ICCC) and exchange (NASDAQ Capital Market) for current market data.
- Check for subsequent filings that may incorporate the press release details by reference.